Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
